Corporate Overview
Development History
Corporate Culture
About Founder
Core Team
R&D Platform
Process Development
Press Releases
Talent Concept
China Biotech Industry: Six foreign-invested enterprises gain approval to engage in stem cell research activities
2024-11-17
Foreign invested enterprises are gaining greater access to the biotech industry in China.
See More
Richard Liqun Wang: China's Cell and Gene Therapy Poised to Take the Lead
2024-09-09
Dr. Richard Liqun Wang, Founder, Chairman, and CEO of Neukio Biotherapeutics, presented the current state, trends, bottlenecks, and prospects of Cell and Gene Therapy (CGT) research and development in China.
Richard Wang: A Seventeen-Year Odyssey of an Overseas PhD Returnee in the Pursuit of Domestic Innovative Drug Development
2024-02-23
Entrepreneur's insight: Innovation poses a formidable challenge that requires significant dedication and hard work. The complexities involved in this endeavor are often underestimated. To become a successful entrepreneur, it is crucial to have a clear goa
Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
2022-09-02
The funds raised will play important roles in accelerating the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and supporting team recruitment and expansion.
Neukio Biotherapeutics has completed $40m Angel round of financing and is committed to developing new NK technology platform and products
2021-10-25
Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for th
Richard Wang: Perks enjoyed by companies based in the FTZ
2023-09-29
Wang Liqun, founder, chairman, and CEO of Neukio Biotherapeutics
Neukio Biotherapeutics Reached Strategic Collaboration with Tofflon Science and Technology Group Co. Ltd to Expedite Large-scale Production of Next Generation Allogenic Cell Therapies
2023-03-21
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies
2022-02-09
(February 9, 2022) EdiGene, Inc. and Neukio Biotherapeutics today announced an R&D collaboration to develop next-generation immune cell therapies.
-442.jpg)